- Incyte Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis
- Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
- Multiple Abstracts from Incyte’s Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience
- Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
- Incyte to Report First Quarter Financial Results
- Incyte Announces the European Commission Approval of Pemazyre® (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement
- Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy
- Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation
- Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021
- Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)
More ▼
Key statistics
On Friday, Incyte Corp (INCY:NSQ) closed at 85.58, 13.32% above the 52 week low of 75.52 set on Mar 04, 2021.
52-week range
Markit short selling activity
| Open | 84.60 |
|---|---|
| High | 85.70 |
| Low | 83.44 |
| Bid | 84.73 |
| Offer | 85.95 |
| Previous close | 84.18 |
| Average volume | 1.07m |
|---|---|
| Shares outstanding | 219.88m |
| Free float | 216.84m |
| P/E (TTM) | -- |
| Market cap | 18.82bn USD |
| EPS (TTM) | -1.39 USD |
Data delayed at least 15 minutes, as of Apr 23 2021 21:00 BST.
More ▼
